Technology
Unprecedented clarity into tumor biology with 100% cancer genome and transcriptome analysis.
Current tests detect only a few frequently mutated genes. Leaving many patients – especially those with less common cancers – without clinically relevant findings and limited treatment options.
The proprietary Isabl GxT platform detects all cancer-associated mutations, reporting the subset of clinically-relevant biomarkers, and revealing new opportunities for precision diagnostics, disease surveillance, and biomarker discovery – for every cancer patient.
The opportunity
Current approaches to sequencing have only been able to provide insight to 1% of the full genome – until now.
One comprehensive test
From biopsy to an actionable report in clinically relevant timeframes, Isabl integrates data from 100% of the cancer DNA, germline DNA, and the transcriptome into a single diagnostic workflow. No more diagnostic odysseys.
Novel biomarker discovery
Comprehensive characterization of the genomic landscape across mutation classes removes any blind spots for biomarker development and identification of responder or non-responder subgroups.
Not just more data, better data
Isabl identifies all cancer associated mutations including mutations that no other cancer diagnostic assay can detect today, improving diagnosis for many patients.
The Isabl Difference
It's not just about having more data – it's about having the right data, delivered in the right format. Isabl looks at the whole picture – and delivers it in a clear and concise report to give you the information you need to provide truly personalized care to your patients.
HRD
Mutational Burden
MSI
Immunophenotypes
Neo-antigens
Gene expression
Non-coding mutations
Rare cancer genes
Common cancer genes
Rearrangments
Fusion genes
Copy number
Other biomarkers
Expression & Immunoprofiling
DNA small mutations
Structural changes
How our process works
Cancer diagnoses and prognoses are complex – but they don't have to be complicated. Isabl simplifies the process significantly, while providing incomparably clear, compelling results.
isabl for oncology
Informed research, evidence-led standards, better patient experience.
Isabl is collaborating with oncologists and cancer centers to evaluate clinical validity and utility across solid and heme cancer indications. Isabl GxT will be available for RUO release in Q2 2024. Now, we're looking for more partners to help continue our learning.
- One comprehensive test from a single biopsy
- Better risk stratification
- End diagnostic odysseys
- Improved treatment planning
- Data driven treatment planning
- Informed eligibility for clinical trials
- Improved diagnosis
isabl for pharma
Decoding Cancer: Uncover Hidden Biomarkers, Enhance Drug Response.
Rare cancers, rare variants – Isabl’s FDA designated Breakthrough technology can help find patients with untapped biomarkers that might predict response.
- Gain accurate mutation detection including gene mutations, allelic imbalances, structural variants, fusion genes, mutation signatures, TMB, MSI, HRD, and gene expression
- Comprehensive assessment of clinical trial eligibility
- Understand why some patients respond to a drug and why others don't
Isabl products
The most comprehensive WGS-based diagnostics.
With our strong scientific foundation and deep technical expertise, Isabl is at the forefront of WGS analysis. Our suite of products will set the course of future cancer care.
Isabl GxT Solid for solid tumors
Cancer whole genome and transcriptome and germline whole genome. Applied to Fresh Frozen (FF) and Formalin-fixed Paraffin Embedded (FFPE) samples with matched blood.
Isabl GxT Heme for hematological cancers
Cancer whole genome and transcriptome (no germline sample required). From blood and bone marrow (BM).
isabl´s core
We are a data-driven company working with advanced analytics.
With a strong scientific foundation, deep technical expertise, and using machine learning/AI to develop next generation biomarkers from WGS data, Isabl is creating one of the largest WGS datasets in the world that captures every relevant genetic biomarker now and in the future.
That means access to best-in-class genomic expertise.
Clinical cancer genomics has made great strides using targeted panels, but we are still missing what happens in 99% of the genome. Moving to whole genome and whole transcriptome sequencing will allow us to find all the key alterations in cancer genomes and help us identify more opportunities for patient tailored therapy.”
